Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Abstract

IntroductionThere is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients.MethodsData were pooled from four phase 3 studies of secukinumab in patients with moderate-to-severe plaque psoriasis. Patients who self-identified as Hispanic were included in the Hispanic subgroup.ResultsEfficacy responses (Psoriasis Area and Severity Index [PASI] 75/90/100 and Investigator’s Global Assessment 2011 modified version 0/1) for secukinumab 300 mg were greater than for etanercept at week 12 in the Hispanic and non-Hispanic patient subgroups. At week 12 with secukinumab 300 mg, PASI 90/100 responses were achieved by 70.6%/35.9% of Hispanic patients and 58.0%/28.1% of non-Hispanic patients. At week 12 with secukinumab 150 mg, PASI 90/100 responses were achieved by 59.5%/25.1% of Hispanic patients and 41.2%/13.4% of non-Hispanic patients. In both subgroups, peak efficacy responses with secukinumab were observed at week 16 and were maintained to week 52.ConclusionsSecukinumab is highly effective for clearing psoriasis in both Hispanic and non-Hispanic patients.FundingNovartis Pharmaceutical Corporation.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-017-0521-z) contains supplementary material, which is available to authorized users.

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study

“…Secukinumab, a recently approved fully human monoclonal antibody targeting IL-17A, neutralizes IL-17A as both homodimer and heterodimer dimeric ligands of IL-17. Secukinumab has demonstrated high efficacy and a favorable safety profile in clinical trials (7)(8)(9). However, these encouraging results have largely been obtained in patient cohorts selected for clinical trials, poorly reflecting the more complex psoriatic patient population observed in a real-world setting (10).…”

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

“…Lower efficacy has been reported in patients with longer durations of psoriasis, a history of psoriatic arthritis or in individuals previously treated with or had failed treatments with biologics . Treatment response can also vary with ethnicity . Weight is also a critical variable that has been frequently reported to affect efficacy, as obesity is a common problem in patients with moderate‐to‐severe psoriasis.…”

Dermatology: how to manage psoriasis and recognize differences in pathophysiology and presentation in patients with skin of colour

“… 106 Hispanic patients were shown to have efficacy greater than that of non-Hispanic patients after 12 weeks of secukinumab treatment in pooled data from phase III RCTs (PASI 90 achieved by 70.6% versus 58.0%, respectively). 107 Finally, a subgroup analysis of Taiwanese and Japanese patients from the ERASURE trial reported that treatment with secukinumab resulted in efficacy similar to that observed in the entire study population. 102 , 108 , 109 …”